No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Bibliographic Details
Main Authors: Johannes Griss, Gudrun Ratzinger, Julia‐Tatjana Maul, Wolfgang Weger, Diamant Thaçi, José Manuel Carrascosa, Constanze Jonak
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Skin Health and Disease
Online Access:https://doi.org/10.1002/ski2.263

Similar Items

Similar Items